Strides Pharma Science Ltd.

NSE: STAR BSE: 532531 SECTOR: Pharmaceuticals & Drugs

585.35
-24.05 (-3.95%)
NSE: 20 Sep 04:12 PM

Price Summary

Today's High

₹ 607.2

Today's Low

₹ 581.5

52 Week High

₹ 999

52 Week Low

₹ 562.55

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.

Company Essentials

Market Cap

5255.12 Cr.

Enterprise Value

6061.02 Cr.

No. of Shares

8.98 Cr.

P/E

86.14

P/B

1.63

Face Value

₹ 10

Div. Yield

0.43%

Book Value (TTM)

₹  358.91

CASH

73.04 Cr.

DEBT

878.94 Cr.

Promoter Holding

29.62%

EPS (TTM)

₹  6.8

Sales Growth

9.79%

ROE

2.45 %

ROCE

4.35 %

Profit Growth

-34.95 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Ratios

Sales Growth

1 Year9.79%
3 Year-1.7%
5 Year-3.52%

Profit Growth

1 Year-34.95%
3 Year-55.56%
5 Year-9.68%

ROE%

1 Year2.45%
3 Year3.22%
5 Year8.2%

ROCE %

1 Year4.35%
3 Year4.51%
5 Year8.16%

Debt/Equity

0.271

Price to Cash Flow

18.58

Interest Cover Ratio

2.70855078896218

CFO/PAT (5 Yr. Avg.)

0.716338301464466

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2021 29.62 26.02
Mar 2021 29.67 32.56
Dec 2020 29.69 40.38
Sep 2020 29.69 37.04
Jun 2020 29.71 46.84
* Figures given above are % of equity capital

 Strengths

 Looks like the company does not have any notable strengths.

 Limitations

  • The company has shown a poor profit growth of -55.5620118698625% for the Past 3 years.
  • The company has shown a poor revenue growth of -1.69643874251025% for the Past 3 years.
  • Company has a poor ROE of 3.21714010978269% over the past 3 years.
  • Company has a poor ROCE of 4.50972316690843% over the past 3 years
  • Company has contingent liabilities of 1789.587 Cr.
  • The company is trading at a high PE of 86.14.
  • Promoter pledging is high as 26.02%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Net Sales 411.01 384.33 421.09 633.6 508.79
Total Expenditure 391.4 373.93 377.63 545.58 503.54
Operating Profit 19.61 10.4 43.46 88.02 5.25
Other Income 23.57 47.37 26.19 23.31 11.69
Interest 15.83 14.42 17.13 17.91 18.09
Depreciation 24.49 24.16 25.15 24.73 26.64
Exceptional Items 0 0 0 0 0
Profit Before Tax 2.86 19.2 27.36 68.7 -27.79
Tax 1.98 5.52 6.88 20.62 -6.56
Profit After Tax 0.89 13.68 20.49 48.08 -21.23
Adjusted EPS (Rs) 0.1 1.53 2.29 5.36 -2.37

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 1381.82 1955.4 1537.44 1691.93 1857.57
Total Expenditure 1269.85 1815.21 1403.1 1487.48 1698.34
Operating Profit 111.97 140.2 134.34 204.46 159.23
Other Income 169.06 1001.72 114.61 93.07 117.09
Interest 71.96 81.97 54.09 66.84 65.34
Depreciation 70.01 114.77 83 94.24 99.34
Exceptional Items -15.16 -29.38 -3.52 0 0
Profit Before Tax 123.9 915.8 108.33 136.45 111.64
Tax 15.36 24.21 -2.04 16.17 33.4
Net Profit 108.54 891.59 110.37 120.28 78.24
Adjusted EPS (Rs.) 12.14 99.62 12.32 13.43 8.72

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 89.42 89.5 89.55 89.57 89.68
Total Reserves 3143.1 3072.52 3167.25 3069.22 3158.38
Borrowings 769.45 2.45 0.15 0 147.54
Other N/C liabilities 25.77 -36.86 -63.27 -37.31 159.89
Current liabilities 1434.16 1104.05 1388.99 1454.95 1590.64
Total Liabilities 5461.9 4231.65 4582.68 4576.42 5146.12
Assets
Net Block 1123.76 497.96 496.73 578.35 576.66
Capital WIP 99.63 86.89 72.56 89.47 81.36
Intangible WIP 58.12 56.97 49.9 22.78 29.31
Investments 1310.77 1531.19 2071.47 2242.91 2462.48
Loans & Advances 204.05 154.76 223.27 237.29 247.33
Other N/C Assets 86.41 404.35 5.16 10.1 5.13
Current Assets 2579.16 1499.54 1663.59 1395.53 1743.86
Total Assets 5461.9 4231.65 4582.68 4576.42 5146.12
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations 123.9 915.8 108.33 136.45 111.64
Adjustment 193.49 -670.77 90.19 130.28 114.15
Changes in Assets & Liabilities 131.16 -161.75 -121.04 -96.91 -109.81
Tax Paid -36.81 -17.68 -37.52 -32.18 166.79
Operating Cash Flow 411.74 65.59 39.97 137.64 282.76
Investing Cash Flow -882.82 432.96 -166.06 62.83 -275.64
Financing Cash Flow -67.24 -706.77 123.26 -203.56 -48.64
Net Cash Flow -538.32 -208.22 -2.83 -3.09 -41.52

Corporate Actions

Investors Details

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Promoters 29.71 29.69 29.69 29.67 29.62
abusha investment & manan... 0.31 0.31 0.31 0.31 0.31
agnus capital llp 0.02 0.02 0 0 0
agnus holdings pvt ltd 0.13 0.13 0 0 0
ambemata securities 0.54 0.54 0.54 0.54 0.54
arun kumar pillai 1.53 1.53 1.55 1.55 1.54
chaitanya d 0.47 0.03 0.03 0.03 0.07
chayadeep properties priv... 0.46 0.46 0 0 0
devendra estates llp 0.92 0.92 0.92 0.92 0.92
devendra kumar s 0.01 0.1 0.1 0.1 0
gayatri nair 0.04 0.04 0.04 0.04 0.04
hemalatha pillai 0.05 0.05 0.07 0.07 0.07
jatin v 0.51 0.51 0.51 0.51 0.51
jitesh d 0.41 0.03 0.03 0.03 0.03
k r lakshmi 0.15 0.15 0.15 0.15 0.15
k r ravishankar 1.4 1.4 1.4 1.4 1.4
karuna ventures private l... 0.02 0.02 0 0 0
lakshmi gopalakrishnan 0.06 0.06 0.06 0.06 0.06
leela v 0.47 0.47 0.47 0.47 0.47
monisha nitin 0.16 0.16 0.17 0.17 0.17
nitin kumar v 0.56 0.56 0.56 0.56 0.59
padmakumar karunakaran pi... 0.19 0.19 0.21 0.21 0.21
pooja srisrimal 0.1 0.1 0.1 0.1 0.1
pronomz ventures llp 14.14 17.83 18.39 18.38 18.37
purushothaman pillai g 0.04 0.04 0.04 0.04 0.04
rahul nair 0.02 0.02 0.02 0.02 0.02
rajeswari amma 0.1 0.1 0 0 0
rajitha gopalakrishnan 0.05 0.05 0.07 0.07 0.07
rupali jatin 0.21 0.21 0.21 0.21 0.21
sajitha pillai 0.09 0.09 0.11 0.11 0.11
sajjan d 0.19 0.25 0.27 0.27 0.2
sequent scientific limite... 3.7 0 0 0 0
shasun leasing and financ... 1.12 1.12 1.12 1.12 1.12
suchi chaitanya srisrimal... 0.1 0.1 0.1 0.1 0.1
triumph venture holdings ... 0.04 0.04 0.04 0.04 0
vimal kumar s 0.29 0.29 0.29 0.29 0.33
vineetha mohanakumar pill... 0.2 0.2 0.21 0.21 0.21
karuna business solutions... 0.67 1.34 1.36 1.36 1.36
vimal kumar s - (huf) 0.13 0.13 0.13 0.13 0.13
lifecell international pr... 0 0 0 0 0
s abhaya kumar huf 0.07 0.07 0.09 0.09 0.09
taru mardia 0.02 0.02 0.02 0.02 0.02
vibha srisrimal 0.02 0.02 0.02 0.02 0.02
abhaya kumar s 0 0 0 0 0.06
PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Public 24.11 28.07 28.5 29.42 29.96
satpal khattar 1.74 1.74 1.74 1.74 1.74
life insurance corporatio... 0 3.9 0 0 4.61
life insurance corporatio... 0 0 5.56 5.56 0
PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
FII/DII 46.18 42.24 41.81 40.9 40.42
government pension fund g... 3.45 3.45 2.97 2.82 2.82
route one fund i, l.p. 3 2.99 2.99 2.99 2.99
route one offshore master... 0 0 0 0 0
bnp paribas arbitrage 2.7 2.77 3 2.89 2.92
brookdale mauritius inter... 1.55 0 0 0 0
hdfc trustee company ltd ... 1.25 1.25 1.25 0 0
life insurance corporatio... 3.63 0 0 0 0
aditya birla sun life tru... 0 0 7.39 0 0
aditya birla sun life tru... 6.96 0 0 0 0
morgan stanley asia (sing... 0 0 0 0 0
satpal khattar 0 0 0 0 0
sbi long term equity fund... 7.31 6.86 6.47 6.47 6.67
route one offshore master... 4.47 4.46 4.46 4.46 0
aditya birla sun life tru... 0 6.54 0 0 0
societe generale - odi 0 2.08 1.27 1.23 0
oman india joint investme... 0 0 1.13 1.13 1.13
aditya birla sun life tru... 0 0 0 6.97 6.5
hdfc trustee company ltd 0 0 0 1.25 0
route one offshore master... 0 0 0 0 4.46
smallcap world fund, inc 0 0 0 0 2.72
societe generale 0 0 0 0 1.23

Ratings & Research Reports

Company Presentations

Company News

Strides Pharma Science informs about disclosure13 Aug 2021, 3:37PM Strides Pharma Science reports consolidated net loss of Rs 205 crore in Q17 Aug 2021, 11:15AM Strides Pharma Science’s arms ink definitive agreement with subsidiaries of Endo 6 Aug 2021, 9:57AM Strides Pharma Science informs about press release6 Aug 2021, 9:52AM Strides Pharma Science’s Puducherry facility successfully completes EU GMP inspection28 Jun 2021, 4:57PM Strides Pharma Science informs about press release28 Jun 2021, 9:59AM Strides Pharma Science informs about disclosure25 Jun 2021, 3:25PM Strides Pharma Science’s arm inks pact with Ennaid Therapeutics15 Jun 2021, 9:09AM Strides Pharma Science informs about press release28 May 2021, 9:24AM Strides Pharma Science informs about grant of options under Strides ESOP 27 May 2021, 4:45PM Strides Pharma Science informs about recommendation of final dividend 27 May 2021, 4:42PM Strides Pharma Science, TLC partner to launch Liposomal Amphotericin B 27 May 2021, 3:27PM Strides Pharma Science informs about disclosure 11 May 2021, 3:22PM Strides Pharma Science informs about disclosure11 May 2021, 2:48PM Strides Pharma Science’s arm, RDIF enter into partnership 19 Mar 2021, 5:14PM Strides Pharma Science informs about press release19 Mar 2021, 10:34AM Strides Pharma Science informs about voting results 17 Mar 2021, 4:16PM Strides Pharma Science informs about press release15 Mar 2021, 11:09AM Strides Pharma Science’s arm receives USFDA’s approval for Potassium Chloride for Oral Solution15 Mar 2021, 10:21AM Strides Pharma Science’s arm gets approval for Ibuprofen Oral Suspension24 Feb 2021, 11:29AM Strides Pharma Science’s arm gets approval for Prednisone Tablets from USFDA12 Feb 2021, 10:51AM Strides to demerge and list biotech business under Stelis Biopharma4 Feb 2021, 2:19PM Strides Pharma Science informs about disclosure28 Jan 2021, 10:26AM Strides Pharma's arm gets USFDA approval for Ursodiol Capsules25 Jan 2021, 2:39PM Strides Pharma Science informs about ratings22 Jan 2021, 10:49AM Strides Pharma Science informs about press release15 Jan 2021, 10:40AM Strides Pharma's arm gets USFDA's nod for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets15 Jan 2021, 10:24AM Strides Pharma Science informs about press release8 Jan 2021, 10:42AM Strides Pharma Science informs about press release18 Dec 2020, 4:57PM Strides Pharma's arm gets USFDA’s approval for Oxybutynin Chloride Tablets18 Dec 2020, 2:38PM Strides Pharma Science’s arm gets USFDA approval for Prednisone Tablets 23 Nov 2020, 1:41PM Strides Pharma Science informs about board meeting23 Oct 2020, 10:47AM Strides Pharma’s arm gets USFDA’s nod for Ethacrynic Acid Tablets20 Oct 2020, 12:00PM Strides Pharma’s arm gets USFDA nod for Butalbital, Acetaminophen, Caffeine Tablets22 Sep 2020, 12:58PM Strides unveils SteriScience as its dedicated arm for sterile injectables14 Sep 2020, 2:37PM Strides Pharma’s arm gets USFDA’s nod for Prednisone Tablets3 Sep 2020, 4:00PM Strides Pharma Science informs about disclosure 24 Aug 2020, 4:20PM Strides Pharma Science informs about disclosure24 Aug 2020, 1:59PM Strides Pharma Science’s arm gets USFDA’s approval for Ursodiol Tablets21 Aug 2020, 12:40PM Strides Pharma Science informs about press release21 Aug 2020, 10:37AM UK MHRA completes inspection at Strides Pharma Science’s Puducherry facility20 Aug 2020, 11:28AM Strides Pharma Science informs about press release19 Aug 2020, 3:20PM Strides Pharma Science informs about press release9 Jul 2020, 10:12AM Strides Pharma’s arm gets nod for Butalbital, Acetaminophen, Caffeine, Codeine Phosphate Capsules9 Jul 2020, 9:54AM Strides Pharma’s arm gets USFDA nod for Triamcinolone Acetonide Ointment2 Jun 2020, 11:44AM Strides Pharma Science develops, commences export of Favipiravir Antiviral tablets29 Apr 2020, 10:04AM Strides Pharma’s arm gets USFDA’s approval for Flucytosine Capsules20 Apr 2020, 11:31AM Strides Pharma Science ceases distribution of ranitidine tablets in America3 Apr 2020, 1:02PM Strides Pharma Science gets EIR from USFDA for Bangalore facility30 Mar 2020, 10:25AM

Strides Pharma Scien Stock Price Analysis and Quick Research Report. Is Strides Pharma Scien an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Strides Pharma Scien and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 282.762 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Strides Pharma Scien has a Debt to Equity ratio of 0.271 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Strides Pharma Scien , the EPS growth was -35.0329143333731 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Strides Pharma Scien has OPM of 8.57202382041878 % which is a bad sign for profitability.
     
  • ROE: Strides Pharma Scien have a poor ROE of 2.44637608654868 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Strides Pharma Scien

X